News Releases

October 2018

October 22, 2018 10/22/2018 Investigational Subcutaneous Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Ulcerative Colitis

October 19, 2018 10/19/2018 Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib)

October 18, 2018 10/18/2018 Takeda receives clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc

October 1, 2018 10/1/2018 Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial

September 2018

September 28, 2018 9/28/2018 Takeda and Lundbeck Submit New Drug Application (NDA) for Vortioxetine in Japan for the Treatment of Major Depressive Disorder (MDD)

September 28, 2018 9/28/2018 Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

September 25, 2018 9/25/2018 Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial

September 21, 2018 9/21/2018 Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

September 21, 2018 9/21/2018 Takeda Obtains Additional Indication and Dosage & Administration for ADCETRIS® as a Frontline Treatment for CD30-positive Hodgkin Lymphoma in Japan